Safety of bone marrow derived mesenchymal stem cell extracellular vesicle injection for lumbar facet joint pain.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2024-01-01 Epub Date: 2024-02-08 DOI:10.2217/rme-2023-0110

James E Wilson, Bobbie A Today, Maria Salazar, Jonathann Kuo, John T Ransom, Amy L Lightner, Grace Chen, Anita Wong

引用次数: 0

Abstract

Aim: A 3-month pilot study to evaluate the safety of injecting a bone marrow-derived mesenchymal stem cell extracellular vesicle advanced investigational product (IP) into the lumbar facet joint space as a treatment for chronic low back pain. Methods: 20 healthy adults were treated with IP injections (0.5 ml/joint) and evaluated by three functional assessments 1, 3, 7, 14, 30, 60 and 90 days later. Results: No adverse effects or complications occurred across the 3-month follow-up. There were no reports of worsening pain. After 3 months group average scores improved significantly (p < 0.0001) in the Severity Index (65.04%), Interference Index (72.09%) and Oswestry Disability Index (58.43%) assessments. Conclusion: IP injections were safe and associated with significant functional improvements.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

骨髓间充质干细胞细胞外囊注射治疗腰椎面关节疼痛的安全性。

目的：一项为期3个月的试验性研究，评估在腰椎面关节间隙注射骨髓间充质干细胞胞外囊高级研究产品（IP）治疗慢性腰痛的安全性。方法：对20名健康成年人进行IP注射（0.5毫升/关节）治疗，并在1、3、7、14、30、60和90天后进行三次功能评估。结果：3 个月的随访期间未出现不良反应或并发症。没有疼痛恶化的报告。3 个月后，治疗组的平均得分明显提高（p 结论：IP 注射是安全的，并与疼痛相关：IP 注射是安全的，并能显著改善功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.

期刊最新文献

Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold. ATMP clinical trials in the UK. Industry updates from the field of stem cell research and regenerative medicine in September 2024. Correction. Industry updates from the field of stem cell research and regenerative medicine in August 2024.